TME Pharma AG
TME Pharma is a clinical-stage company focused on developing novel therapies for the treatment of the most aggressive cancers. They specialize in targeting the tumor microenvironment (TME) to break tumor protection barriers and block tumor repair, working in combination with other treatments to enhance therapeutic impact. Their clinical programs in glioblastoma and pancreatic cancer have shown promising results, with further development planned. Their approach involves neutralizing chemokines in the TME to weaken tumor defenses and improve treatment outcomes.
Industries
Nr. of Employees
medium (51-250)
Products
Pipeline of chemokine-neutralizing clinical-stage therapeutic candidates
Clinical-stage therapeutic candidates that neutralize chemokines in the tumor microenvironment; development focus includes glioblastoma and pancreatic cancer and evaluation in combination regimens.
Corporate presentation with clinical data highlights
Investor and scientific presentation summarizing clinical results, including conference presentation data showing improved survival with a combination regimen.
Pipeline of chemokine-neutralizing clinical-stage therapeutic candidates
Clinical-stage therapeutic candidates that neutralize chemokines in the tumor microenvironment; development focus includes glioblastoma and pancreatic cancer and evaluation in combination regimens.
Corporate presentation with clinical data highlights
Investor and scientific presentation summarizing clinical results, including conference presentation data showing improved survival with a combination regimen.
Services
Partnering with external organizations to co-develop oncology therapeutics targeting the tumor microenvironment.
Design and conduct of clinical-stage programs and management of clinical trials in aggressive cancers.
Partnering with external organizations to co-develop oncology therapeutics targeting the tumor microenvironment.
Design and conduct of clinical-stage programs and management of clinical trials in aggressive cancers.
Expertise Areas
- Tumor microenvironment therapeutics
- Oncology clinical development (glioblastoma, pancreatic cancer)
- Chemokine-targeted drug discovery
- Combination therapy strategy development
Key Technologies
- Chemokine neutralization
- Tumor microenvironment modulation
- Mirror-image aptamer-style nucleic acid therapeutics
- Combination regimens with anti-angiogenic agents and radiotherapy
News & Updates
Aram Mangasarian, March 27 – 29, New Orleans, USA
Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing significant survival improvement.
Aram Mangasarian, March 27 – 29, New Orleans, USA
Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing significant survival improvement.